Trial Profile
A Retrospective Chart Study Evaluating the Role of Small Cystic Macular Changes as a Prognostic Factor for the Recurrence of Macular Oedema (ME) in Patients Treated with Ranibizumab (IVR) or Bevacizumab (IVB) for Macular Oedema (ME) Secondary to Branch Retinal Vein Occlusion (BRVO)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Jan 2018
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Ranibizumab (Primary)
- Indications Retinal oedema
- Focus Therapeutic Use
- 17 Jan 2018 New trial record